The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium

March 31, 2025 9:00 AM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced its abstract has been accepted for presentation at the Society for Clinical Vascular Surgery (SCVS) 52nd Annual Symposium being held March 29-April 2, 2025 in Austin, TX.As part of the SCVS Symposium, Dr. Cassius Iyad Ochoa Chaar, Associate Professor of Surgery, Yale School of...

Read more

International Stem Cell Corporation Announces 2024 Fourth Quarter and Year-End Results

March 31, 2025 8:30 AM

International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced fourth quarter and year-end financial results for the period ending on December 31, 2024.FY 2024 Financial Highlights:Revenues increased to $9.09 million in 2024, an...

Read more

Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure

March 31, 2025 8:00 AM

Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced in addition to developing TH104 for the proposed indication of moderate-to-severe chronic pruritus in patients with primary biliary cholangitis ("PBC"), which utilizes an approved active ingredient, now formulated as a buccal film, Tharimmune is seeking to develop TH104 for the additional...

Read more

Aspira Receives $1.5 million Milestone Payment from the ARPA-H Sprint for Women’s Health Award

March 31, 2025 8:00 AM

Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the successful completion of the second development milestone of its Advanced Research Projects Agency for Health (ARPA-H) award. As a result of satisfying the second development milestone, Aspira received a $1.5 million cash payment under the terms of the related...

Read more

Lifeloc Technologies Reports 2024 Full Year Results

March 28, 2025 6:10 PM

Lifeloc Technologies, Inc. (OTC PINK:LCTC), a global leader in the development and manufacturing of breath alcohol testing devices, has announced financial results for the 2024 fiscal year ended December 31, 2024.2024 Financial HighlightsLifeloc Technologies posted annual net revenue of $8.538 million resulting in a net loss of ($1.053) million in 2024, or ($0.41) per diluted share. These results compare to net revenue of $9.330 million for...

Read more

Solaxa Announces Phase 3 Clinical Trial for Spinocerebellar Ataxia Type 27B

March 28, 2025 12:00 PM

Solaxa Inc., a biopharmaceutical public benefit corporation focused on rare neurological conditions, has announced plans to conduct a registrational clinical trial evaluating its investigational therapy, SLX-100, for spinocerebellar ataxia type 27B (SCA27B).This pivotal-powered study will be funded in part by a $7.3 million dollar grant awarded to Dr. Susan Perlman, MD, at the University of California, Los Angeles by the Congressionally Directed...

Read more

Prolocor(R) Announces Publication in Circulation: Cardiovascular Interventions. Results Demonstrate That the Prolocor pFCG(TM) Test Predicts Risk of Subsequent Cardiovascular Events Regardless of Treatment Strategy (Percutaneous Coronary Intervention or Medical Management Alone)

March 28, 2025 9:00 AM

Prolocor, Inc., a healthcare startup developing the innovative diagnostic Prolocor pFCGTM test that identifies patients at higher and lower risk of thrombotic events (heart attack, stroke, and death), announced today a publication entitled Predictive Value of Platelet FcγRIIa in Patients Treated with Percutaneous Coronary Intervention Compared with Medical Therapy Alone after Myocardial Infarction in the journal Circulation: Cardiovascular...

Read more

Vicore to Participate in the Van Lanschot Kempen Life Sciences Conference

March 28, 2025 3:10 AM

Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that Ahmed Mousa, Chief Executive Officer, will be a panelist during the idiopathic pulmonary fibrosis (IPF) plenary session at the 2025 Van Lanschot Kempen Life Sciences Conference.Location: Amsterdam, the NetherlandsPanelist: Ahmed Mousa, CEOIPF Plenary Session Date and Time: Wednesday, April...

Read more

Aspira Women's Health Reports Fourth Quarter and Full Year 2024 Financial Results

March 27, 2025 4:00 PM

Aspira Women's Health Inc. ("Aspira" or the "Company") (Nasdaq:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today reported its financial results for the fourth quarter and year ended December 31, 2024. Select financial results are as follows:Fourth Quarter 2024 and Recent Financial Highlights• Product revenue increased 9.5% to $2.3 million for the three months ended...

Read more

Alligator Bioscience Publishes Annual Report for 2024

March 27, 2025 2:30 PM

Alligator Bioscience (STO:ATORX) today announced that the Annual Report for 2024, as well as the company's Remuneration Report, has been published. Because of environmental and cost reasons, Alligator Bioscience has chosen not to print the annual report.The Annual Report and the Remuneration Report are attached as PDFs and are available on the company's website.For further information, please contact:Søren Bregenholt, CEOE-mail:...

Read more

Minutes from Annual General Meeting in FluoGuide A/S

March 27, 2025 11:15 AM

FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company" held its annual general meeting on 27 March 2025.To the shareholders of FluoGuide A/S.The Annual General Meeting was held Thursday 27 March 2025 at 02:00 PM (CET) at the Company's premises Titanhus, Titangade 9-13, meeting room - Kronos, DK-2200 Copenhagen N, Denmark.Notice: Represented at the annual general meeting was share capital of nominal DKK 596,840.70 corresponding to 5,968,407 votes...

Read more

Bulletin from the Extraordinary General Meeting in Alligator Bioscience AB

March 27, 2025 9:30 AM

Alligator Bioscience (STO:ATORX) Today, on 27 March 2025, an extraordinary general meeting was held in Alligator Bioscience AB. A summary of the adopted resolutions follows below.Resolution on guidelines for remuneration to senior executivesThe meeting resolved, in accordance with the board of directors' proposal, to adopt new guidelines for remuneration to the company's senior executives.Resolution on reduction of the share capital to cover...

Read more

Imagene Laboratory Receives Accreditation From College of American Pathologists

March 27, 2025 9:15 AM

The Accreditation Committee of the College of American Pathologists (CAP) has recently awarded accreditation to Imagene Laboratory, Phoenix, Arizona, based on the results of a recent on‐site inspection as part of CAP's Accreditation Programs. Recognized for rigorous and robust standards, CAP accreditation elevates quality and mitigates risk, an important way that laboratories can contribute to improved patient outcomes."We are proud that the...

Read more

Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at 2025 Annual MDS Foundation Congress

March 27, 2025 3:20 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) New analysis and biomarker data strengthens understanding of bexmarilimab's potentialTURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, today announces that data from its ongoing BEXMAB study evaluating bexmarilimab in patients with high-risk myelodysplastic syndromes (HR-MDS) have been...

Read more

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma

March 26, 2025 9:00 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its collaboration partner, PeriNess Ltd. ("PeriNess"), has entered into a Clinical Study Agreement (the "Agreement") to support an exploratory clinical study of Xenetic's systemic DNase I candidate, XBIO-015, in patients with...

Read more

IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances

March 26, 2025 9:00 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced additional positive interim results from its ongoing Phase 2 clinical trial on IGC-AD1, an investigational treatment for agitation in dementia due to Alzheimer's disease. Based on the interim analysis at week 2 sleep disturbance was reduced by about 71% (p=.012) and at week 6 about 78% (p=.02) for those on the active medication. These values indicate a...

Read more

Notice of Annual General Meeting of Vicore Pharma Holding AB (publ)

March 26, 2025 4:00 AM

Vicore Pharma Holding (STO:VICO)The shareholders of Vicore Pharma Holding AB (publ), Reg. No. 556680-3804 ("Vicore Pharma" or the "company"), with its registered offices in Stockholm, are summoned to the Annual General Meeting on Tuesday 6 May 2025 at 15.00 in the premises of the law firm Vinge at Smålandsgatan 20, SE-111 46 Stockholm, Sweden. Registration starts at 14.45.Shareholders can participate in the Annual General Meeting by attending...

Read more

Vicore Publishes the Annual Report for 2024

March 26, 2025 3:20 AM

Vicore Pharma Holding (STO:VICO) Stockholm, March 26, 2025 - Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced the publication of the Annual Report for the financial year 2024.The Annual Report for the financial year 2024 is available on the company's website: https://vicorepharma.com/investors/financial-reports/For further information, please...

Read more

DiviTum(R) TKa Data in Combination with Inflammation Proteins Presented at the AACR Meeting Enhance Precision to Predict Efficacy of Immunotherapy

March 26, 2025 3:20 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, a leader in blood-based biomarker assays in oncology, today announces that an abstract with DiviTum TKa in a biomarker algorithm will be presented by Karolinska Institutet (KI) at the annual AACR meeting in Chicago on April 25-30, 2025, providing the first evidence that DiviTum TKa in combination with inflammation protein biomarkers significantly improves the ability to...

Read more

Notice to Annual General Meeting in BioInvent International AB

March 25, 2025 5:20 AM

BioInvent International (STO:BINV) The shareholders of BioInvent International AB (publ), Reg. No 556537-7263, are hereby invited to attend the Annual General Meeting to be held at 4.00 p.m., 29 April 2025 at Elite Hotel Ideon on Scheelevägen 27 in Lund, Sweden.The Board of Directors has decided that shareholders shall be able to exercise their voting rights at the Annual General Meeting also by voting in advance by post in accordance with the...

Read more